ASH 2021 Five-Year Follow-Up of Keynote-087: Pembrolizumab Monotherapy in R/R cHL

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

ASH 2021 Five-Year Follow-Up of Keynote-087: Pembrolizumab Monotherapy in R/R cHL

By ASH 2021 Conference Coverage on VuMedi FEATURING Alex Herrera

270 views

March 24, 2022

0 Comments

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

NCCN Guidelines for the Treatment of cHL: A New Standard of Care

40:21

Fred Hutch 13th Annual Comprehensive Hematology & Oncology Review Course

Overview of Hematopoietic Cell Transplantation

Feat. R. Salit

41:20

SOHO Highlights: State of the Art and Next Questions

SOHO Highlights - State of the Art & Next Questions: Hodgkin Lym…

Feat. N. Bartlett

17:51

Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies

Chronic GVHD: A Case-Based Discussion

Feat. L. Perry

15:18

UNC Lineberger Comprehensive Cancer Center

Hodgkin Lymphoma Management: Updates for 2023

Feat. N. Grover

40:13

Fred Hutch 13th Annual Comprehensive Hematology & Oncology Review Course

Overview of Diagnosis and Treatment of Hodgkin's Lymphoma

Feat. R. C. Lynch

30:24

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Treatment of Older Patients With HL in the …

Feat. A. Evens

42:09

University of Colorado Department of Medicine

Immunotherapy in Lymphomas: The Present and the Future

Feat. M. Kamdar

27:47

City of Hope

Chronic GVHD: Review Advances in Prevention, Novel Endpoints, and Ta…

Feat. I. Amanam

28:57

Total Health

Highlights From Key Hematology Trials at ASCO® 2023

Feat. J. Strauss

15:24

Total Health

2023 ASCO® Direct Philadelphia: Hodgkin Lymphoma Updates

Feat. J. Svoboda

23:24

SOHO Brazil 2023

2023 SOHO® Brazil: "How I Sequence New Agents in First and Seco…

Feat. A. Moskowitz

08:02

ASH 2022 Conference Coverage

ASH 2022 Results From Phase III BMT CTN 1703: Post-Transplant Cyclop…

Feat. S. Holtan

10:21

SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Next Questions: HL

Feat. A. Herrera

15:56

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

2024 Updates in Management of Hodgkin Lymphoma

Feat. J. Svoboda

08:21

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "The Phase 2 KEYNOTE-B68 Trial - Efficacy …

Feat. A. Mcdonald

08:30

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "PD-1 Blockade Before AutoSCT in R/R Classic…

Feat. S. Desai

12:19

SOHO Brazil 2023

2023 SOHO® Brazil: "Are We About to Abandon Transplant in HL?&q…

Feat. A. Moskowitz

32:39

MyCancerHaven

Experts Discuss the Basics of Allogeneic Stem Cell Transplant

Feat. R. Vij, M. Christopher

13:48

Anna Sureda

Login

Login

Join VuMedi

ASH 2021 Five-Year Follow-Up of Keynote-087: Pembrolizumab Monotherapy in R/R cHL

Related Content